Physician profile
Benjamin Brian Bert
NPI 1518129964
$2,673.39
in general payments reported to CMS, 2019-2025
20 companies · $731 in 2025
The $731 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $273 · 2020: $262 · 2021: $123 · 2022: $294 · 2023: $606 · 2024: $384 · 2025: $731.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,721.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,721.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $490.56 | 2019-2025 | Cequa |
| Alcon Vision LLC | $479.75 | 2021-2025 | Rocklatan, Clareon, Tryptyr |
| Bausch & Lomb Americas INC. | $364.46 | 2023-2025 | Miebo, Vyzulta, Lotemax Sm |
| Merz Pharmaceuticals, LLC | $285.31 | 2021-2024 | Xeomin |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $195.37 | 2019-2020 | |
| Harrow Eye, LLC | $174.59 | 2025 | Vevye |
| Oyster Point Pharma, INC. | $165.22 | 2024-2025 | Tyrvaya, Ryzumvi |
| Shire North American Group INC | $96.10 | 2019 | |
| Aerie Pharmaceuticals, INC. | $79.43 | 2020-2021 | |
| Thea Pharma INC. | $66.89 | 2023-2024 | Iyuzeh |
| Eyevance Pharmaceuticals LLC | $63.12 | 2020 | |
| Johnson & Johnson Surgical Vision, INC. | $45.56 | 2022-2023 | Tecnis Iol |
| Ani Pharmaceuticals, INC. | $26.78 | 2024 | Purified Cortrophin Gel |
| Amgen INC. | $26.43 | 2024 | Tepezza |
| Rayner Intraocular Lenses Limited | $25.56 | 2025 | Omidria |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $24.26 | 2019 | |
| Mallinckrodt Enterprises LLC | $24.01 | 2019 | |
| Horizon Therapeutics Plc | $21.79 | 2022 | |
| Kala Pharmaceuticals, INC. | $18.20 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Bert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.